LIPOSOMAL FORMULATIONS IN CANCER THERAPY: BASIC CONCEPTS TO ADVANCED STRATEGIES
Abstract
Liposomes, a phospholipid bilayer vesicular system is extensively being used and studied for drug delivery applications in cancer therapy. The reason behind is advantages that liposomes offer such as their biocompatible and non-immunogenic nature, improved bioavailability of anticancer drugs and versatility of efficiently encapsulating both hydrophilic and hydrophobic drugs. Recent advances such as surface functionalization and modifications of liposomes have played very crucial part to overcome limitations associated with conventional liposomal system which eventually has opened up many new and potential ways of cancer therapy. Surface decoration of liposomes with targeting ligand can lead to actively targeted site specific therapy of solid tumor. Recently, a number of liposomal formulations for cancer treatment are already in clinic and many are still under active research. This review discusses about the basics of liposomes such as structural, components, methods of preparation, and mainly focuses on recent advances of liposomal technology which includes various kinds of surface modification of currently used liposomes with efficient passive or active targeted drug delivery along with its mechanism, the advantages and associated drawbacks and their potential applications in treatment of cancer.
Keywords:
Liposomes, Targeted Drug Delivery, Cancer Therapy, Solid Tumor, Surface ModificationDOI
https://doi.org/10.25004/IJPSDR.2018.100505References
1. Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, et al. The Global Burden of Cancer 2013. JAMA Oncol. 2015;1:505-27.
2. Bhardwaj A, Srivastava SK, Singh S, Arora S, Tyagi N, Andrews J, et al. CXCL12/CXCR4 signaling counteracts docetaxel-induced microtubule stabilization via p21-activated kinase 4-dependent activation of LIM domain kinase 1. Oncotarget. 2014;5:11490-500.
3. Bhatt P, Vhora I, Patil S, Amrutiya J, Bhattacharya C, Misra A, et al. Role of antibodies in diagnosis and treatment of ovarian cancer: Basic approach and clinical status. J Control Release. 2016;226:148-67.
4. Richardson DS, Kelsey SM, Johnson SA, Tighe M, Cavenagh JD, Newland AC. Early evaluation of liposomal daunorubicin (DaunoXome, Nexstar) in the treatment of relapsed and refractory lymphoma. Invest New Drugs. 1997;15:247-53.
5. Batist G, Barton J, Chaikin P, Swenson C, Welles L. Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy. Expert Opin Pharmacother. 2002;3:1739-51.
6. Takeda to Acquire IDM Pharma, Adding MEPACT (Mifamurtide), the First Treatment Approved for Osteosarcoma in More Than 20 Years.
7. Silverman JA, Deitcher SR. Marqibo(R) (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine. Cancer Chemother Pharmacol. 2013;71:555-64.
8. Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update. Retina. 2005;25:119-34.
9. Merrimack and Baxalta Announce Publication of the ONIVYDE™ (irinotecan liposome injection) NAPOLI-1 Study in The Lancet.
10. Patel J. Liposomal doxorubicin: Doxil®. Journal of Oncology Pharmacy Practice. 1996;2:201-10.
11. Zhang JA, Anyarambhatla G, Ma L, Ugwu S, Xuan T, Sardone T, et al. Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation. Eur J Pharm Biopharm. 2005;59:177-87.
12. Mangala LS, Han HD, Lopez-Berestein G, Sood AK. Liposomal siRNA for ovarian cancer. Methods Mol Biol. 2009;555:29-42.
13. Ozpolat B, Lopez-Berestein G, Adamson P, Fu CJ, Williams AH. Pharmacokinetics of intravenously administered liposomal all-trans-retinoic acid (ATRA) and orally administered ATRA in healthy volunteers. J Pharm Pharm Sci. 2003;6:292-301.
14. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. International Journal of Nanomedicine. 2006;1:297-315.
15. Zhang JA, Xuan T, Parmar M, Ma L, Ugwu S, Ali S, et al. Development and characterization of a novel liposome-based formulation of SN-38. Int J Pharm. 2004;270:93-107.
16. Suenaga M, Mizunuma N, Matsusaka S, Shinozaki E, Ozaka M, Ogura M, et al. Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study. Drug Des Devel Ther. 2015;9:3099-108.
17. Wetzler M, Thomas DA, Wang ES, Shepard R, Ford LA, Heffner TL, et al. Phase I/II trial of nanomolecular liposomal annamycin in adult patients with relapsed/refractory acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2013;13:430-4.
18. Dark GG, Calvert AH, Grimshaw R, Poole C, Swenerton K, Kaye S, et al. Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group. J Clin Oncol. 2005;23:1859-66.
19. Chang H-I, Yeh M-K. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. International Journal of Nanomedicine. 2012;7:49-60.
20. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65:36-48.
21. Seiden MV, Muggia F, Astrow A, Matulonis U, Campos S, Roche M, et al. A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer. Gynecol Oncol. 2004;93:229-32.
22. Yarmolenko PS, Zhao Y, Landon C, Spasojevic I, Yuan F, Needham D, et al. Comparative effects of thermosensitive doxorubicin-containing liposomes and hyperthermia in human and murine tumours. Int J Hyperthermia. 2010;26:485-98.
23. Chang TC, Shiah HS, Yang CH, Yeh KH, Cheng AL, Shen BN, et al. Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients. Cancer Chemother Pharmacol. 2015;75:579-86.
24. Zamboni WC, Ramalingam S, Friedland DM, Edwards RP, Stoller RG, Strychor S, et al. Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies. Clin Cancer Res. 2009;15:1466-72.
25. Lohr JM, Haas SL, Bechstein WO, Bodoky G, Cwiertka K, Fischbach W, et al. Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial. Ann Oncol. 2012;23:1214-22.
26. Liposome: A versatile platform for targeted delivery of drugs." Shri B. M. Shah College of Pharmaceutical. Sanjay S. Patel (M. Pharm), 2006.
27. Deshmukh RR, Gawale SV, Bhagwat MK, Ahire PA, Derle ND. A review on: liposomes. WJPPS. 2016; 5(3):506-517.
28. Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urologic oncology. 2008;26:57-64.
29. Bhatt P, Lalani R, Vhora I, Patil S, Amrutiya J, Misra A, et al. Liposomes encapsulating native and cyclodextrin enclosed paclitaxel: Enhanced loading efficiency and its pharmacokinetic evaluation. International Journal of Pharmaceutics. 2018;536:95-107.
30. Dhule SS, Penfornis P, Frazier T, Walker R, Feldman J, Tan G, et al. Curcumin-loaded gamma-cyclodextrin liposomal nanoparticles as delivery vehicles for osteosarcoma. Nanomedicine. 2012;8:440-51.
31. McCormack B, Gregoriadis G. Entrapment of cyclodextrin-drug complexes into liposomes: potential advantages in drug delivery. J Drug Target. 1994;2:449-54.
32. Bhatt P, Lalani R, Mashru R, Misra A. Abstract 2065: Anti-FSHR antibody Fab’ fragment conjugated immunoliposomes loaded with cyclodextrin-paclitaxel complex for improved in vitro efficacy on ovarian cancer cells. Cancer Research. 2016; 76(14):2065.
33. Vhora I, Patil S, Bhatt P, Misra A. Protein- and Peptide-drug conjugates: an emerging drug delivery technology. Adv Protein Chem Struct Biol. 2015; 98:1-55.
34. Vhora I, Patil S, Bhatt P, Gandhi R, Baradia D, Misra A. Receptor-targeted drug delivery: current perspective and challenges. Ther Deliv. 2014; 5:1007-24.
35. Sawant RR, Torchilin VP. Challenges in development of targeted liposomal therapeutics. AAPS J. 2012; 14:303-15.
36. Zhu L, Kate P, Torchilin VP. Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting. ACS Nano. 2012; 6:3491-8.
37. Sawant RR, Torchilin VP. Liposomes as ‘smart’ pharmaceutical nanocarriers. Soft Matter. 2010; 6:4026-44.
2. Bhardwaj A, Srivastava SK, Singh S, Arora S, Tyagi N, Andrews J, et al. CXCL12/CXCR4 signaling counteracts docetaxel-induced microtubule stabilization via p21-activated kinase 4-dependent activation of LIM domain kinase 1. Oncotarget. 2014;5:11490-500.
3. Bhatt P, Vhora I, Patil S, Amrutiya J, Bhattacharya C, Misra A, et al. Role of antibodies in diagnosis and treatment of ovarian cancer: Basic approach and clinical status. J Control Release. 2016;226:148-67.
4. Richardson DS, Kelsey SM, Johnson SA, Tighe M, Cavenagh JD, Newland AC. Early evaluation of liposomal daunorubicin (DaunoXome, Nexstar) in the treatment of relapsed and refractory lymphoma. Invest New Drugs. 1997;15:247-53.
5. Batist G, Barton J, Chaikin P, Swenson C, Welles L. Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy. Expert Opin Pharmacother. 2002;3:1739-51.
6. Takeda to Acquire IDM Pharma, Adding MEPACT (Mifamurtide), the First Treatment Approved for Osteosarcoma in More Than 20 Years.
7. Silverman JA, Deitcher SR. Marqibo(R) (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine. Cancer Chemother Pharmacol. 2013;71:555-64.
8. Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update. Retina. 2005;25:119-34.
9. Merrimack and Baxalta Announce Publication of the ONIVYDE™ (irinotecan liposome injection) NAPOLI-1 Study in The Lancet.
10. Patel J. Liposomal doxorubicin: Doxil®. Journal of Oncology Pharmacy Practice. 1996;2:201-10.
11. Zhang JA, Anyarambhatla G, Ma L, Ugwu S, Xuan T, Sardone T, et al. Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation. Eur J Pharm Biopharm. 2005;59:177-87.
12. Mangala LS, Han HD, Lopez-Berestein G, Sood AK. Liposomal siRNA for ovarian cancer. Methods Mol Biol. 2009;555:29-42.
13. Ozpolat B, Lopez-Berestein G, Adamson P, Fu CJ, Williams AH. Pharmacokinetics of intravenously administered liposomal all-trans-retinoic acid (ATRA) and orally administered ATRA in healthy volunteers. J Pharm Pharm Sci. 2003;6:292-301.
14. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. International Journal of Nanomedicine. 2006;1:297-315.
15. Zhang JA, Xuan T, Parmar M, Ma L, Ugwu S, Ali S, et al. Development and characterization of a novel liposome-based formulation of SN-38. Int J Pharm. 2004;270:93-107.
16. Suenaga M, Mizunuma N, Matsusaka S, Shinozaki E, Ozaka M, Ogura M, et al. Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study. Drug Des Devel Ther. 2015;9:3099-108.
17. Wetzler M, Thomas DA, Wang ES, Shepard R, Ford LA, Heffner TL, et al. Phase I/II trial of nanomolecular liposomal annamycin in adult patients with relapsed/refractory acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2013;13:430-4.
18. Dark GG, Calvert AH, Grimshaw R, Poole C, Swenerton K, Kaye S, et al. Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group. J Clin Oncol. 2005;23:1859-66.
19. Chang H-I, Yeh M-K. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. International Journal of Nanomedicine. 2012;7:49-60.
20. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65:36-48.
21. Seiden MV, Muggia F, Astrow A, Matulonis U, Campos S, Roche M, et al. A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer. Gynecol Oncol. 2004;93:229-32.
22. Yarmolenko PS, Zhao Y, Landon C, Spasojevic I, Yuan F, Needham D, et al. Comparative effects of thermosensitive doxorubicin-containing liposomes and hyperthermia in human and murine tumours. Int J Hyperthermia. 2010;26:485-98.
23. Chang TC, Shiah HS, Yang CH, Yeh KH, Cheng AL, Shen BN, et al. Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients. Cancer Chemother Pharmacol. 2015;75:579-86.
24. Zamboni WC, Ramalingam S, Friedland DM, Edwards RP, Stoller RG, Strychor S, et al. Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies. Clin Cancer Res. 2009;15:1466-72.
25. Lohr JM, Haas SL, Bechstein WO, Bodoky G, Cwiertka K, Fischbach W, et al. Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial. Ann Oncol. 2012;23:1214-22.
26. Liposome: A versatile platform for targeted delivery of drugs." Shri B. M. Shah College of Pharmaceutical. Sanjay S. Patel (M. Pharm), 2006.
27. Deshmukh RR, Gawale SV, Bhagwat MK, Ahire PA, Derle ND. A review on: liposomes. WJPPS. 2016; 5(3):506-517.
28. Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urologic oncology. 2008;26:57-64.
29. Bhatt P, Lalani R, Vhora I, Patil S, Amrutiya J, Misra A, et al. Liposomes encapsulating native and cyclodextrin enclosed paclitaxel: Enhanced loading efficiency and its pharmacokinetic evaluation. International Journal of Pharmaceutics. 2018;536:95-107.
30. Dhule SS, Penfornis P, Frazier T, Walker R, Feldman J, Tan G, et al. Curcumin-loaded gamma-cyclodextrin liposomal nanoparticles as delivery vehicles for osteosarcoma. Nanomedicine. 2012;8:440-51.
31. McCormack B, Gregoriadis G. Entrapment of cyclodextrin-drug complexes into liposomes: potential advantages in drug delivery. J Drug Target. 1994;2:449-54.
32. Bhatt P, Lalani R, Mashru R, Misra A. Abstract 2065: Anti-FSHR antibody Fab’ fragment conjugated immunoliposomes loaded with cyclodextrin-paclitaxel complex for improved in vitro efficacy on ovarian cancer cells. Cancer Research. 2016; 76(14):2065.
33. Vhora I, Patil S, Bhatt P, Misra A. Protein- and Peptide-drug conjugates: an emerging drug delivery technology. Adv Protein Chem Struct Biol. 2015; 98:1-55.
34. Vhora I, Patil S, Bhatt P, Gandhi R, Baradia D, Misra A. Receptor-targeted drug delivery: current perspective and challenges. Ther Deliv. 2014; 5:1007-24.
35. Sawant RR, Torchilin VP. Challenges in development of targeted liposomal therapeutics. AAPS J. 2012; 14:303-15.
36. Zhu L, Kate P, Torchilin VP. Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting. ACS Nano. 2012; 6:3491-8.
37. Sawant RR, Torchilin VP. Liposomes as ‘smart’ pharmaceutical nanocarriers. Soft Matter. 2010; 6:4026-44.
Published
01-09-2018
Statistics
Abstract Display: 735 
PDF Downloads: 743
Dimension Badge
How to Cite
“LIPOSOMAL FORMULATIONS IN CANCER THERAPY: BASIC CONCEPTS TO ADVANCED STRATEGIES”. International Journal of Pharmaceutical Sciences and Drug Research, vol. 10, no. 5, Sept. 2018, pp. 386-93, https://doi.org/10.25004/IJPSDR.2018.100505.
Issue
Section
Review Article
How to Cite
“LIPOSOMAL FORMULATIONS IN CANCER THERAPY: BASIC CONCEPTS TO ADVANCED STRATEGIES”. International Journal of Pharmaceutical Sciences and Drug Research, vol. 10, no. 5, Sept. 2018, pp. 386-93, https://doi.org/10.25004/IJPSDR.2018.100505.
